Pipeline
Pipeline
Early Discovery
Lead Optimization
Pre Clinical
Phase 1
Neurodegeneration (NURR1)
LF101 (Lead)
Central-Nervous System Disease
(1st generation)
Small Molecule (IP)
Neurodegeneration (NURR1)
LF102
Parkinson’s Disease (1st generation)
Small Molecule (Oral)
- 40%
Neurodegeneration (NURR1)
LF201
Parkinson’s Disease
(2nd generation)
Small Molecule (Intranasal)
- 40%
Oncology (VRK1)
LF501
VRK1 (IHC 2+) Breast Cancer
VRK1 (IHC 2+) Lung Cancer
Small Molecule Oral (PO)
- 32%
Metabolic disorders
(Nor1, NR4R3)
LF601
Type 2 Diabetes
VRK1 (IHC 2+) Lung Cancer
Small Molecule Oral (PO)
- 32%
Neurodegeneration
(a-Synuclein)
LF701
Dementia with Lewy bodies
Small Molecule Oral (PO)
- 19%
Neurodegeneration(NURR1)
LF101 (Lead)
Central-Nervous System Disease (1st generation)
Small Molecule (IP)
Discovery
- 23%
Neurodegeneration(NURR1)
LF102
Parkinson’s Disease (1st generation)
Small Molecule (Oral)
Lead Optimization
- 45%
Neurodegeneration(NURR1)
LF103
Parkinson’s Disease (2nd generation)
Small Molecule (Intranasal)
Lead Optimization
- 45%
Oncology (VRK1)
LF501
VRK1 (IHC 2+) Breast Cancer & Lung Cancer
Small Molecule Oral (PO)
Lead Optimization
- 40%
Metabolic disorders (Nor1, NR4R3)
LF601
Type 2 Diabetes
Small Molecule Oral (PO)
Discovery
- 23%
Neurodegeneration(a-Synuclein)
LF701
Dementia with Lewy bodies
Small Molecule Oral (PO)
Discovery
- 23%